BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 16611810)

  • 1. Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders.
    Tofaris GK; Garcia Reitböck P; Humby T; Lambourne SL; O'Connell M; Ghetti B; Gossage H; Emson PC; Wilkinson LS; Goedert M; Spillantini MG
    J Neurosci; 2006 Apr; 26(15):3942-50. PubMed ID: 16611810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
    Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
    Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter.
    Matsuoka Y; Vila M; Lincoln S; McCormack A; Picciano M; LaFrancois J; Yu X; Dickson D; Langston WJ; McGowan E; Farrer M; Hardy J; Duff K; Przedborski S; Di Monte DA
    Neurobiol Dis; 2001 Jun; 8(3):535-9. PubMed ID: 11442360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice.
    Gomez-Isla T; Irizarry MC; Mariash A; Cheung B; Soto O; Schrump S; Sondel J; Kotilinek L; Day J; Schwarzschild MA; Cha JH; Newell K; Miller DW; Uéda K; Young AB; Hyman BT; Ashe KH
    Neurobiol Aging; 2003; 24(2):245-58. PubMed ID: 12498958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transgenic mice overexpressing tyrosine-to-cysteine mutant human alpha-synuclein: a progressive neurodegenerative model of diffuse Lewy body disease.
    Zhou W; Milder JB; Freed CR
    J Biol Chem; 2008 Apr; 283(15):9863-70. PubMed ID: 18238775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
    J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.
    Oliveras-Salvá M; Van der Perren A; Casadei N; Stroobants S; Nuber S; D'Hooge R; Van den Haute C; Baekelandt V
    Mol Neurodegener; 2013 Nov; 8():44. PubMed ID: 24267638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders.
    Masliah E; Rockenstein E; Veinbergs I; Mallory M; Hashimoto M; Takeda A; Sagara Y; Sisk A; Mucke L
    Science; 2000 Feb; 287(5456):1265-9. PubMed ID: 10678833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD8 T cell nigral infiltration precedes synucleinopathy in early stages of Parkinson's disease.
    Galiano-Landeira J; Torra A; Vila M; Bové J
    Brain; 2020 Dec; 143(12):3717-3733. PubMed ID: 33118032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The center of olfactory bulb-seeded α-synucleinopathy is the limbic system and the ensuing pathology is higher in male than in female mice.
    Mason DM; Wang Y; Bhatia TN; Miner KM; Trbojevic SA; Stolz JF; Luk KC; Leak RK
    Brain Pathol; 2019 Nov; 29(6):741-770. PubMed ID: 30854742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra.
    St Martin JL; Klucken J; Outeiro TF; Nguyen P; Keller-McGandy C; Cantuti-Castelvetri I; Grammatopoulos TN; Standaert DG; Hyman BT; McLean PJ
    J Neurochem; 2007 Mar; 100(6):1449-57. PubMed ID: 17241127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TIGAR inclusion pathology is specific for Lewy body diseases.
    López KLR; Simpson JE; Watson LC; Mortiboys H; Hautbergue GM; Bandmann O; Highley JR
    Brain Res; 2019 Mar; 1706():218-223. PubMed ID: 30267647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of truncated human alpha-synuclein (1-120) on dopaminergic cells in a transgenic mouse model of Parkinson's disease.
    Michell AW; Tofaris GK; Gossage H; Tyers P; Spillantini MG; Barker RA
    Cell Transplant; 2007; 16(5):461-74. PubMed ID: 17708336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters.
    Rockenstein E; Mallory M; Hashimoto M; Song D; Shults CW; Lang I; Masliah E
    J Neurosci Res; 2002 Jun; 68(5):568-78. PubMed ID: 12111846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha-synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: lessons from viral transduction of knockout mice.
    Alerte TN; Akinfolarin AA; Friedrich EE; Mader SA; Hong CS; Perez RG
    Neurosci Lett; 2008 Apr; 435(1):24-9. PubMed ID: 18314273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
    Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions.
    Fleming SM; Mulligan CK; Richter F; Mortazavi F; Lemesre V; Frias C; Zhu C; Stewart A; Gozes I; Morimoto B; Chesselet MF
    Mol Cell Neurosci; 2011 Mar; 46(3):597-606. PubMed ID: 21193046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The nigro-striatal and nigro-amygdaloid pathways undergo different degeneration processes in brains of dementia with Lewy bodies.
    Iseki E; Marui W; Yamamoto R; Togo T; Katsuse O; Kato M; Iwatsubo T; Kosaka K; Arai H
    Neurosci Lett; 2005 May 20-27; 380(1-2):161-5. PubMed ID: 15854770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology.
    Ulusoy A; Febbraro F; Jensen PH; Kirik D; Romero-Ramos M
    Eur J Neurosci; 2010 Aug; 32(3):409-22. PubMed ID: 20704592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.